



ASX ANNOUNCEMENT

**Imugene Receptor Mimic Technology
Patent Granted in United States**

Key Receptor Mimic Patent granted in the most important international market

17 January 2005, Sydney: Imugene (ASX: IMU) has been granted patent protection for its *Receptor Mimic Technology (RMT)* in the United States through to 2020. The *RMT* is the platform for existing and new Imugene products for pigs, poultry and cattle, including one of the Company's lead products to prevent *E. coli* post weaning diarrhoea in pigs.

Receptor mimic products act as an extremely efficient biological 'sponge', binding toxins or disease causing organisms and harmlessly carrying them out of the body. Unlike new or existing antibiotics or antimicrobials, there is no potential for food residues, no chance of resistance developing and the products are safe for widespread use in all mammalian species.

The *RMT* also has many applications in human medicine and Imugene holds an equity interest in *BioMimic*, the company with the commercial rights to develop *RMT* products for the human market.

Imugene Managing Director, Dr Warwick Lamb commented, "The granting of this key patent is very significant because the United States is the highest value market for our products. This patent grant covers *RMT* use in both animals and humans. The *RMT E. coli* preventative for pigs is currently undergoing clinical trials.

Post weaning diarrhoea caused by *E. coli* is one of the most economically damaging bacterial diseases in pig production. The market for *E. coli* disease preventative treatments in pigs is estimated to be over US\$450 million per annum. We anticipate expanding the *E. coli* product for use in poultry and possibly cattle.

The patent has previously been granted in Australia and New Zealand.

END

More information:

Dr Warwick Lamb,
Imugene's Managing Director
+61 2 9870 7330

Mr Graham Dowland,
Imugene's Executive Chairman
+61 8 9322 9189

Mr Rudi Michelson
Monsoon Communications
+61 3 9620 3333

ABOUT IMUGENE:

Imugene specialises in commercialising animal health products for production animals including pigs, poultry and cattle.

Imugene's products safely prevent disease and reduce or eliminate antibiotics and harmful chemicals in animals. Animal antibiotics and chemicals in the human food chain have been linked to the emergence of dangerous resistant bacteria in people and food residues.

Imugene owns the worldwide rights to two platform technologies. The **Receptor Mimic Technology** for gastrointestinal diseases of pigs and potentially all other animal species. Secondly, the **Adenoviral Vector Delivery System** for pigs and poultry delivers Imugene's highly effective *poultry productivity enhancer*.

Imugene's poultry and pig portfolio is targeting a worldwide US\$3 billion annual market and replace existing chemical and antibiotic products. Consumer demands for residue free food and health regulatory pressures will bolster Imugene's prospects.

Visit the Imugene Website: www.imugene.com